About Xentech
Xentech is a company based in Paris (France) founded in 2006. Xentech has raised $765 thousand across 2 funding rounds from investors including European Union and Aurinvest. Xentech offers products and services including PDX Models, CDX Models, and In Vivo Services. Xentech operates in a competitive market with competitors including Certis Oncology Solutions, Yecuris, zPREDICTA, Chengdu Zhongke Aoge Biotechnology and Sagres Discovery, among others.
- Headquarter Paris, France
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$765 K (USD)
in 2 rounds
-
Latest Funding Round
$162.9 K (USD), Grant
Jan 01, 2016
-
Investors
European Union
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Xentech
Xentech offers a comprehensive portfolio of products and services, including PDX Models, CDX Models, and In Vivo Services.
Human tumor-based models for preclinical drug testing and profiling
Cell-derived models for immuno-oncology research applications
Services for in vivo experiments in drug development
Funding Insights of Xentech
Xentech has successfully raised a total of $765K across 2 strategic funding rounds. The most recent funding activity was a Grant round of $162.9 thousand completed in January 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Xentech
Xentech has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union and Aurinvest.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Xentech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Xentech
Investment portfolio details for Xentech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Xentech
Detailed financials for Xentech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Xentech Comparisons
Peer comparison for Xentech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Xentech
Xentech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Certis Oncology Solutions, Yecuris, zPREDICTA, Chengdu Zhongke Aoge Biotechnology and Sagres Discovery, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Oncology-based in-vivo drug development services are provided.
|
|
| Locked | Locked | Locked |
Humanized liver rodent models are developed for biology research.
|
|
| Locked | Locked | Locked |
Tumor-specific in vitro 3D models are supplied for drug development.
|
|
| Locked | Locked | Locked |
Xenotransplantation technology for human-compatible organs is developed.
|
|
| Locked | Locked | Locked |
Creates innovative mouse models to analyze genes causing cancer diseases.
|
Detailed competitors of Xentech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Xentech
Complete news archive for Xentech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Xentech
Xentech was founded in 2006 and raised its 1st funding round 2 years after it was founded.
Xentech is headquartered in Paris, France.
Xentech is a funded company, having raised a total of $765K across 2 funding rounds to date.
Xentech was established in 2006 as a spin-off from Institut Curie in Paris, France, focusing on oncology research. A collection of patient-derived xenograft models is maintained, supporting translational drug development through fee-for-service contracts. Preclinical studies in collaboration with biopharma and academic partners are conducted, with emphasis on breast cancer models. Operations center on addressing needs in early-stage cancer therapeutics.
Xentech's top competitors include Certis Oncology Solutions, Yecuris and zPREDICTA.
Xentech offers PDX Models, CDX Models, and In Vivo Services.
Xentech has 2 investors. Key investors include European Union, and Aurinvest.